AI and Software in Life Sciences

A curated newsletter covering the tools, platforms, and ideas shaping the digital transformation of life sciences.

By subscribing you agree to receive emails from Life Sciences Digital.

AI and Software in Life Sciences

A curated newsletter covering the tools, platforms, and ideas shaping the digital transformation of life sciences.

By subscribing you agree to receive emails from Life Sciences Digital.

What you'll find in the newsletter

Industry signals that matter

Analysis of the developments shaping digital life sciences — major partnerships, platform strategies, acquisitions, and technology shifts across biotech, pharma, and health tech.

The software layer of modern science

Updates on the tools, platforms, and infrastructure powering research, clinical development, and laboratory operations.

Tools and opportunities from the ecosystem

Selected software tools from the Life Sciences Digital database, along with relevant conferences, initiatives, and opportunities across the field.

Dive into our latest issues ↓

Danaher and Waters Open Their Instruments to AI Agents. Biohub Assembles $1.8 Billion for Virtual Biology. Agilent Buys the Pathology Operating Layer.

Last issue Microsoft Research introduced Quine, five top-twenty pharma companies showed that pooled proprietary data beats public co-folding models, and the US Department of Veterans Affairs committed up to $775.72 million to roll out AI medical scribes across its hospitals. Over the past two weeks the focus moved down to the lab bench again. Danaher announced its first AI-powered autonomous lab and a collaboration with NVIDIA to build AI into its instruments, Waters opened its LC-MS software to AI agents, and Biohub, the DOE, the NIH, Google DeepMind, Isomorphic Labs and Meta lined up $1.8 billion for the data that virtual cell models need. Instrument makers are redesigning their hardware to be driven by models. The data commons for virtual biology now has a budget. And the software layers around pathology, discovery and trial operations are consolidating around fewer platforms.

Microsoft Research Launches Project Quine. Five Pharma Rivals Pool Their Data to Beat Every Public Model.

Last issue frontier AI labs went deeper into life sciences, with Novo Nordisk signing Claude across R&D, Anthropic opening its own wet biology lab, and ARPA-H funding the first autonomous cardiology AI programmes. During the last two weeks the pattern spread: Microsoft Research introduced Quine, a multimodal world model of biology built with the Broad Institute, and used it to rank thousands of pancreatic cancer compounds in a weekend. Five top-twenty pharma companies confirmed that their proprietary structural data, pooled through federated learning, trains a protein co-folding model that beats everything built on public structures alone. Genentech committed over $1.5 billion to Earendil Labs' AI antibody platform, AbbVie signed Iambic days before Iambic filed to go public, and the US Department of Veterans Affairs put a $775.72 million ceiling on ambient AI across its hospital system. Three frontier labs now have their own biology research programmes in the open, pharma is choosing which AI partners its R&D runs through, and federal healthcare has priced ambient AI as production infrastructure.

Novo Signs Anthropic Across R&D. Anthropic Opens Its Own Biology Lab. ARPA-H Puts Federal Money Behind Autonomous Cardiology AI.

Last issue IQVIA rebuilt clinical development around agents, CluePoints and Weave Bio put agents into clinical data review and regulatory drafting, and Anthropic published a standard for wiring them into lab instruments. Over the past two weeks the frontier AI labs themselves went a step deeper into life sciences: Novo Nordisk signed a direct collaboration with Anthropic to run Claude across research and development. Anthropic set up its own wet biology lab in the San Francisco Bay Area to run experiments alongside its models. OpenAI wired ChatGPT into Epic and pointed the same product at ClinicalTrials.gov and PubMed. And ARPA-H committed federal money to three companies building autonomous clinical AI for cardiovascular care. The frontier AI labs are moving into pharma R&D. The wet lab is moving into the AI lab. And the federal validation pathway for autonomous clinical AI is being written.

About us

Life Sciences Digital is a curated database of software tools used across biotechnology, pharmaceutical research, and related scientific fields.

The platform catalogs tools used in areas such as data analysis, laboratory automation, research collaboration, and digital infrastructure for life sciences organizations.

The goal is simple: make it easier to discover and understand the growing ecosystem of software supporting modern scientific work.

Browse life sciences tools →

Stay informed

Life sciences are becoming increasingly digital — from AI-driven research to the growing ecosystem of software used across laboratories, biotech, and pharma.

Our newsletter highlights the most relevant developments, tools, and industry signals shaping this shift.

Stay ahead.

By subscribing you agree to receive emails from Life Sciences Digital.